Sulindac Hepatotoxicity: A Case Report and Review

References

• Kwan K. C., Duggan D. E. Pharmacokinetics of sulindac. Acta Rheum. Belg. 1977; 1: 168–178
   PubMedGoogle Scholar
• Van Arman C. G., Risley E. A., Nuss G. W. Pharmacologic properties of an anti-inflammatory agent, 5-fluoro-2-methyl-(p-methylsulfinylbenzylidene)-indene-3-yl-acetic acid. Fed. Proc. 1972; 31: 577, abs
   Google Scholar
• Hucker H. B., Stauffer S. C., White S. D., Rhodes R. E., Arison B. H., Umbenhauer E. R., Bower R. J., McMahon F. G. Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1 (p-[methylsulfinyl]-benzylidenyl)-indene-3-acetic acid in the rat, dog, rheses monkey, and man. Drug Met. Disp. 1973; 1: 721–736
   PubMed Web of Science ®Google Scholar
• Van Arman C. G., Risley E. A., Nuss G. W., Hucker H. B., Duggan D. E. Pharmacology of sulindac. Clinoril in the treatment of rheumatic disorders, E. C. Huskisson, P. F. Franchimont. Raven Press, New York 1976; 9–36
   Google Scholar
• Duggan D. E., Hooke K. F., Risley E. A., Shen T. Y., Van Arman C. G. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther. 1977; 201: 8–13
   PubMed Web of Science ®Google Scholar
• Duggan D. E., Hare L. E., Ditzler C. a., Lei B. W., Kwan K. C. The disposition of sulindac. Clin. Pharmacol. Ther. 1977; 21: 326–355
   PubMed Web of Science ®Google Scholar
• Hucker H. B., Stauffer S. C., Bower R. J., Umbenhauer E. R., McMahon F. G. Metabolism of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-(p-[methylsulfinyl]-benzylidene-3-acetic acid (I) in man and animals. Fed. Proc 1972; 31: 577, abs
   Google Scholar
• Swanson B. N., Boppana V. K., Vlasses P. H., Holmes G. I., Monsell K., Ferguson R. K. Sulindac disposition when given once or twice daily. Clin. Pharmacol. Ther. 1982; 32: 397–403
   PubMed Web of Science ®Google Scholar
• Dujovne C. A., Pitterman A., Vincek W. C., Dobrinska M. R., Davies R. O., Duggan D. E. Enterohepatic circulation of sulindac and metabolites. Clin. Pharmacol. Ther. 1983; 33: 172–177
   PubMed Web of Science ®Google Scholar
• Calabro J. J., Andelman S. Y., Caldwell J. R., Gerber R. C., Hamaty D., Kaplan H., Maltz B. A., Parsons J. L., Saville P., Tretbar H. C., Ward J. R. A Multicenter trial of sulindac in osteoarthritis of the hip. Clin. Pharmacol. Ther. 1977; 22: 358–363
   PubMed Web of Science ®Google Scholar
• Dieppe P. A., Burry N. C., Grahame R., Perera T. Sulindac in osteoarthroses of the hip. Rheumatol. Rehabil. 1976; 15: 112–115
   PubMedGoogle Scholar
• Huskisson E. C., Scott J., Sulindac. Trials of a new anti-inflammatory drug. Ann. Rheum. Pis. 1976; 37: 89–92
   Web of Science ®Google Scholar
• Liebling M. R., Altman R. D., Benedek T. G., Bennahum D. A., Blaschke J. A., Bower R. J., Calabro J. J., Caldwell J. R., Collins R. L., Felt J., Hamaty D., Jimenen C. V., Umbenhauer E. R., Wilkens R. F. A double-blind multicenter trial of sulindac (MG-213) in the treatment of ankylosing spondylitis. Arthritis Rheum. 1975; 18: 411
   Web of Science ®Google Scholar
• Calabro J. J., Khoury M. I., Smyth C. J. Clinoril in acute gout. Acta Rheum. Belg. 1975; 8: 163–166
   Google Scholar
• Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Sulindac: A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 1978; 16: 97–114
   PubMed Web of Science ®Google Scholar
• Simon L. S., Mills J. A. Nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 1980; 302: 1179–1185
   PubMed Web of Science ®Google Scholar
• Simon L. S., Mills J. A. Nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 1980; 302: 1237–1243
   PubMed Web of Science ®Google Scholar
• Paulus H. E. FDA Arthritis Advisory Committee Meeting. Arthritis Rheum. 1982; 125: 1124–1125
   Google Scholar
• Lewis J. H. Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin. Pharm. 1984; 3: 128–138
   PubMedGoogle Scholar
• Whittaker S. J., Amar J. N., Wanless I. R., Heathcote J. Sulindac hepatotoxicity. Gut 1982; 23: 875–877
   PubMed Web of Science ®Google Scholar
• Giroux Y., Moreau M., Kass T. G. Cholestatic jaundice caused by sulindac. Can. J. Surg. 1982; 25: 334–335
   PubMed Web of Science ®Google Scholar
• Dhand A. K., LaBreque D. R., Metzger J. Sulindac (Clinoril) hepatitis. Gastroenterology 1981; 80: 585–586
   PubMed Web of Science ®Google Scholar
• Kaul A., Reddy J. C., Fagman E., Smith G. F. Hepatitis associated with use of sulindac in a child. J. Pediatr. 1981; 99: 650–651
   PubMed Web of Science ®Google Scholar
• Park G. D., Spector R., Headstream T., Goldberg M. Serious adverse reactions associated with sulindac. Arch. Intern. Med. 1982; 142: 1292–1294
   PubMed Web of Science ®Google Scholar
• Anderson R. J. Severe reaction associated with sulindac administration. N. Engl. J. Med. 1979; 300: 735–736
   PubMed Web of Science ®Google Scholar
• Smith F. E., Lindberg P. J. Life-threatening hypersensivity to sullndac. J. Am. Med. Assoc. 1980; 244: 269–270
   PubMedGoogle Scholar
• Wolfe P. B. Sullndac and jaundice. Ann. Intern. Med. 1979; 91: 656
   PubMed Web of Science ®Google Scholar
• Levitt L., Pearson R. W. Sulindac-induced Stevens-Johnson toxic epidermal necrolysis syndrome. J. Am. Med. Assoc 1980; 243: 1262–1263
   PubMed Web of Science ®Google Scholar
• Stambaugh J. E., Gordon R. L., Geller R. Leukopenia and thrombocytopenin secondary to clinoril therapy. Lancet 1980; 2: 594
   PubMed Web of Science ®Google Scholar
• Goldstein J., Laskin D. A., Ginsberg G. H. Sullndac associated with pancreatitis. Ann. Intern. Med. 1980; 93: 151
   PubMed Web of Science ®Google Scholar
• Lilly E. L. Pancreatitis after administration of sullndac. J. Am. Med. Assoc 1981; 246: 2680
   Web of Science ®Google Scholar
• Memon A. N. Pancreatitis and sullndac. Ann. Intern. Med. 1982; 97: 139
   PubMedGoogle Scholar
• Kelsey W. M., Scharyj M. Fatal hepatitis probably due to indomethacin. J. Am. Med. Assoc., 199: 586–587
   Web of Science ®Google Scholar
• Fenech F. F., Bannister W. H., Grech J. L. Hepatitis with biliverdinaemia in association with indomethacin therapy. Brit. Med. J. 1967; 3: 155–156
   PubMed Web of Science ®Google Scholar
• Russell A. S., Sturge R. A., Smith M. A. Serum transaminases during salicylate therapy. Brit. Med. J. 1971; 2: 428–429
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J. Effects of aspirin and acetaminophen on the liver. Arch. Intern. Med. 1981; 141: 333–342
   PubMed Web of Science ®Google Scholar
• Seaman W. E., Plotz P. H. Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers. Arthritis Rheum. 1976; 19: 155–160
   PubMed Web of Science ®Google Scholar
• Sternlieb P., Robinson R. M. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. N.Y. State J. Med. 1978; 78: 1239–1243
   PubMedGoogle Scholar
• Sternlieb P., Robinson R. M. Side effects of ibuprofen. Ann. Intern. Med. 1980; 92: 570
   PubMed Web of Science ®Google Scholar
• Stempel D. A., Miller J. J. Lymphopenia and hepatic toxicity with ibuprofen. J. Pedlatr. 1977; 90: 657–658
   PubMed Web of Science ®Google Scholar
• Law I. P., Knight H. Jaundice associated with Naproxen. N. Engl. J. Med. 1976; 295: 1201
   PubMed Web of Science ®Google Scholar
• Bass B. H. Jaundice associated with Naproxen. Lancet 1974; J: 998
   Google Scholar
• Taggart H. M., Alderdice J. M. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Brit. Med. J. 1982; 284: 1372
   PubMed Web of Science ®Google Scholar
• Goudie B. M., Birnie G. F., Watkinson G., MacSween R. N.M., Kissen L. H., Cunningham N. E. Jaundice associated with the use of benoxaprofen. Lancet 1982; 1: 959
   PubMed Web of Science ®Google Scholar
• Prescott L. F., Leslie P. J. Side effects of benoxaprofen. Brit. Med. J. 1982; 284: 1783
   Google Scholar
• Fisher B. M., McArthur J. M. Side effects of benoxaprofen. Brit. Med. J. 1982; 284: 1783
   Google Scholar
• Firth H., Wilcock G. K., Esiri M. Side effects of benoxaprofen. Brit. Med. J. 1982; 284: 1784
   Google Scholar
• Anonymous. Benoxaprofen. Brit. Med. J. 1982; 285: 459–460
   PubMed Web of Science ®Google Scholar
• Dunk A. A., Walt R. P., Jenkins W. J., Sherlock S. S. Diclofenac hepatitis. Brit. Med. J. 1982; 284: 1605–1606
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J. Anti-inflammatory and other drugs employed in the treatment of rheumatic and musculoskeletal disease. Hepatotoxlcity: The adverse effects of drugs and other chemicals on the liver. Appleton-Century-Crofts, New York 1978; 418–435
   Google Scholar
• Ludwig J. Drug effects on the liver: A compilation of drugs and drug-related hepatic diseases. Dig. Pis. Sci. 1979; 24: 785–796
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J. The expression of hepatotoxlcity. Hepatotoxlcity: The adverse effects of drugs and other chemicals on the liver. Appleton-Century-Crofts, New York 1978; 47–90
   Google Scholar
• Zimmerman H. J. Classification of hepatotoxins and mechanisms of toxicity. Hepatotoxlcity: The adverse effects of drugs and other chemicals on the liver. Appleton-Century-Crofts, New York 1978; 91–121
   Google Scholar
• Zimmerman H. J. Drug-induced liver disease. Hepatotoxlcity: The adverse effects of drugs and other chemicals on the liver. Appleton-Century-Crofts, New York 1978; 349–369
   Google Scholar
• Zimmerman H. J. Drug toxicity: Spectrum of clinical lesions. Drug reactions and the liver, M. Davis, J. M. Tredger, R. Williams. Pitman Medical, London 1981; 35–53
   Google Scholar
• Scheuer P. J. Drug hepatotoxlcity: Range of pathological lesions. Drug reactions and the liver, M. Davis, J. M. Tredger, R. Williams. Pitman Medical, London 1981; 54–57
   Google Scholar
• Russell I. J. Reaction to sulindac. Ann. Intern. Med. 1980; 92: 716–717
   Web of Science ®Google Scholar
• Levltes R., Halfltz G., Klrubakaran M. Febrile reaction to sulindac. J. Am. Med. Assoc 1981; 246: 213–214
   Web of Science ®Google Scholar
• Burrlsh G. F., Brian Katz L. Sullndac-lnduced anaphylaxis. Ann. Emerg. Med. 1981; 10: 154–155
   PubMedGoogle Scholar
• Sprung D. J. Sulindac causing a hypersensitivity reaction with peripheral and mediastinal lymphadenopathy. Ann. Intern. Med. 1982; 97: 564
   PubMed Web of Science ®Google Scholar
• Fein M. Sulindac and pneumonitis. Ann. Intern. Med. 1981; 95: 245
   PubMed Web of Science ®Google Scholar
• Ballas Z. K., Donta S. T. Sulindac-induced aseptic meningitis. Arch. Intern. Med. 1982; 142: 165–166
   PubMed Web of Science ®Google Scholar
• Romeril K. R., Duke D. S., Hollings P. E. Sullndac-lnduced agranulocytosis and bone marrow culture. Lancet 1981; 2: 523
   PubMedGoogle Scholar
• Mitchell J. R., Jollows D. J. Metabolic activation of drugs to toxic substances. Gastroenterology 1975; 68: 392–410
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Jollows D. J., Potter W. Z., Davis D. C., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis: I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 1973; 187: 185–194
   PubMed Web of Science ®Google Scholar
• Jollow D. J., Mitchell J. R., Potter W. Z., Davis D. C., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis: II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 1973; 187: 195–202
   PubMed Web of Science ®Google Scholar
• Potter W. Z., Davis D. C., Mitchell J. R., Jollow D. J., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis: III. Cytochrome P-450-mediated covalent binding in vitro. J. Pharmacol. Exp. Ther. 1973; 187: 203–210
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Jollow D. J., Potter W. Z., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis: IV. Protective role of glutathione. J. Pharmacol. Exp. Ther. 1973; 187: 211–217
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Thorgeirsson S. S., Potter W. Z., Jollow D. J., Keiser H. Acetaminophen-induced hepatic injury: Protective role of glutathione in man and rationale for therapy. Clin. Pharmacol. Ther. 1974; 29: 676–684
   Google Scholar
• Spielberg S. S., Gordon G. B. Glutathione synthetase-deficlent lymphocytes and acetaminophen toxicity. Clin. Pharmacol. Ther. 1981; 29: 51–55
   PubMed Web of Science ®Google Scholar
• Gillette J. R. An integrated approach to the study of chemically reactive metabolites of acetaminophen. Arch. Intern. Med. 1981; 14: 375–379
   Google Scholar
• Davis D. S. Drug hepatotoxicity: Formation and importance of reactive metabolites. Drug reactions and the liver, M. Davis, J. M. Tredger, R. Williams. Pitman Medical, London 1981; 12–18
   Google Scholar
• Spielberg S. S., Gordon G. B., Blake D. A., Goldstein D. A., Herlong H. F. Predisposition to phenytoin hepatotoxicity assessed in vitro. N. Engl. J. Med. 1981; 305: 722–727
   PubMed Web of Science ®Google Scholar
• Rumack B. H., Peterson R. G. Acetaminophen overdose: Incidence diagnosis and managment in 416 patients. Pediatrics 1978; 62: 898–903
   PubMed Web of Science ®Google Scholar
• Rumack B. H., Peterson R. C., Koch G. G., Amara I. A. Acetaminophen overdose: 662 cases with evaluation of oral acetyl cysteine treatment. Arch. Intern. Med. 1981; 141: 380–385
   PubMed Web of Science ®Google Scholar
• Prescott L. F. Treatment of severe acetaminophen poisoning with intravenous acetylcysteine. Arch. Intern. Med. 1981; 141: 386–389
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J. Effects of aspirin and acetaminophen on the liver. Arch. Intern. Med. 1981; 141: 333–342
   PubMed Web of Science ®Google Scholar
• Portman B., Talbot I. C., Day D. W., Davidson A. R., Murray-Lyon I. M., Williams A. R. Histopathological changes in the liver following a paracetamol overdose: Correlation with clinical and biochemical parameters. J. Pathology 1975; 117: 169–181
   PubMed Web of Science ®Google Scholar
• Vale J. A., Meredith T. J., Goulding R. Treatment of acetaminophen poisoning: The use of oral methionine. Arch. Intern. Med. 1981; 141: 394–396
   PubMed Web of Science ®Google Scholar
• Prescott L. F., Matthew H. Cysteamine for paracetamol overdosage. Lancet 1974; 1: 998
   Google Scholar
• Hayes A. H. Therapeutic implications of drug interactions with acetaminophen and aspirin. Arch. Intern. Med. 1981; 141: 301–304
   PubMed Web of Science ®Google Scholar
• Penry J. K., Newmark M. E. The use of antiepileptic drugs. Ann. Intern. Med. 1979; 90: 207–218
   PubMed Web of Science ®Google Scholar
• Conney A. H., Burns J. J. Metabolic interactions among environmental chemicals and drugs: Environmental chemicals that alter microsomal activity may influence the safety and efficacy of drugs. Science 1972; 178: 576–586
   PubMed Web of Science ®Google Scholar
• Wright N., Prescott L. F. Potentiation by previous drug therapy of hepatotoxicity following paracetamol overdosage. Scot. Med. J. 1973; 18: 56–58
   PubMed Web of Science ®Google Scholar
• Pagliaro L., Campesi G., Aguglia F. Barbiturate jaundice. Gastroenterology 1969; 56: 938–943
   PubMedGoogle Scholar
• Lieber C. S., Decarli M. Metabolic effects of alcohol on the liver. Metabolic aspects of alcoholism, C. S. Lieber. University Park Press, Baltimore 1977; 31–79
   Google Scholar
• Geokas M. C., Lieber C. S., French S., Halsted C. H. Ethanol, the liver, and the gastrointestinal tract. Ann. Intern. Med. 1981; 95: 198–211
   PubMed Web of Science ®Google Scholar
• Emby D. J., Fraser B. N. Hepatotoxicity of paracetamol enhanced by ingestion of alcohol: Report of two cases. S. Afr. Med. J. 1977; 51: 208–209
   PubMed Web of Science ®Google Scholar
• Goldfinger R., Ahmed K. S., Pitchumoni C. S., Weseley S. A. Concomitant alcohol and drug abuse enhancing acetaminophen toxicity. Am. J. Gastroenterology 1978; 70: 385–388
   PubMed Web of Science ®Google Scholar
• Kromhout J. P., Holtzmann J. D., McClain C. J. Potentiation of acetaminophen hepatotoxicity by alcohol. Gastroenterology 1979; 26: 1288
   Google Scholar
• McClain C. J., Kromhout J. P., Peterson F. J., Holtzman J. L. Potentiation of acetaminophen hepatotoxicity by alcohol. J. Am. Med. Assoc 1980; 244: 251–253
   PubMed Web of Science ®Google Scholar
• Juhl R. P., Van Thiel D. H., Dittert L. W., Albert K. S., Smith R. B. Ibuprofen and sulindac kinetics in alcoholic liver disease. Clin. Pharmacol. Ther. 1983; 34: 104–109
   PubMed Web of Science ®Google Scholar
• Parker W. A., Shearer C. A. Phenytoin hepatotoxicity: A case report and review. Neurology 1979; 29: 175–178
   PubMed Web of Science ®Google Scholar
• Lee T. J., Carney C. N., Lapis J. L., Higgins T., Fallon H. J. Diphenylhydantoin-induced hepatic neciusis. Gastroenterology 1976; 70: 422–424
   PubMed Web of Science ®Google Scholar
• Harinasuta U., Zimmerman H. J. Diphenylhydantoin sodium hepatitis. J. Am. Med. Assoc 1968; 203: 1015–1018
   Web of Science ®Google Scholar
• Campbell C. B., McGuffie C., Weedon A. P., Powell L. W. Cholestatic liver disease associated with diphenylhydantoin therapy. Am. J. Dig. Pis. 1977; 22: 255–262
   PubMedGoogle Scholar
• Conrad K. A., Nyman D. W. Effects of metoprolol and propranolol on theophylline elimination. Clin. Pharmacol. Ther. 1980; 28: 463–467
   PubMed Web of Science ®Google Scholar
• Bunning R. D., Barth W. F. Sulindac: A potentially renal-sparing nonsteroidal anti-inflammatory drug. J. Am. Med. Assoc. 1982; 248: 2864–2867
   PubMed Web of Science ®Google Scholar
• Cinbattoni G., Cinotti G. A., Pierucci A., Simonetti B. M., Manzi M., Pugliese F., Barsotti P., Pecci G., Taggi F., Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. N. Engl. J. Med. 1984; 310: 279–283
   PubMed Web of Science ®Google Scholar
• Lomvardias S., Pinn V. W., Wadhwa M. L., Koshy K. M., Heller M. Nephrotic syndrome associated with sulindac. N. Engl. J. Med. 1981; 304: 424
   PubMed Web of Science ®Google Scholar
• Whelton A., Bender W., Vaghaiwalla F., Hall-Craggs M., Solez K. Sulindac and renal impairment. J. Am. Med. Assoc. 1983; 249: 2892–2893
   PubMed Web of Science ®Google Scholar
• Clive D. M., Stoff J. S. Renal syndromes associated with non-steroidal anti-inflammatory drugs. N. Engl. J. Med. 1984; 310: 563–572
   PubMed Web of Science ®Google Scholar
• Hamdy R. C., Murnane B., Perera N., Woodcock K., Koch I. M. The pharmacokinetics of benoxaprofen in elderly subjects. Eur. J. Rheumatol 1982; 5: 69–75
   PubMedGoogle Scholar
• Kamal A., Koch I. M. Pharmacokinetic studies of benoxaprofen in geriatric patients. Eur. J. Rheumatol. 1982; 5: 76–81
   PubMed Web of Science ®Google Scholar
• Dollery C. T. The reporting of drug reactions: Values and limitations. Drug reactions and the liver, M. Davis, J. M. Tredger, R. Williams. Pitman Medical, London 1981; 4–11
   Google Scholar
• Halsey P., Cardoe N. Benoxaprofen: Side-effect profile in 300 patients. Brit. Med. J. 1982; 284: 1365–1368
   PubMed Web of Science ®Google Scholar
• Anonymous. $6 million oraflex award is not reduced. Am. Med. News 1984; 27: 27
   Google Scholar
• Anonymous. Oraflex case spurs congress to denounce FDA drug regulations. Med. World News 1983; 24: 86–87
   PubMedGoogle Scholar
• Neuvonen P. J., Elonen E. Effect of activialeu charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur. J. Clin. Pharmacol. 1980; 17: 51–57
   PubMed Web of Science ®Google Scholar
• Goldberg M. J., Berlinger W. G. Treatment of phenobarbital overdose with activated charcoal. J. Am. Med. Assoc 1982; 247: 2400–2401
   PubMed Web of Science ®Google Scholar
• Berg M. J., Berlinger W. G., Goldberg M. J., Spector R., Johnson G. F. Acceleration of the body clearance of phenobarbital by oral activated charcoal. N. Engl. J. Med. 1982; 307: 642–644
   PubMed Web of Science ®Google Scholar
• Pond S. M., Olson K. R., Osterloh J. D., Tong T. G. Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. J. Am. Med. Assoc 1984; 251: 3104–3108
   PubMed Web of Science ®Google Scholar
• Aronoff G. R., Ozawa T., DeSante K. A., Nash J. F., Ridolfo A. S. Benoxaprofen kinetics in renal impairment. Clin. Pharmacol. Ther. 1982; 32: 190–194
   PubMed Web of Science ®Google Scholar
• Rooney P., Buchanan W., Haigh B. S., Roylance P. J., Rhymer A. R. Evaluation clinique du sulindac in medicine generale: Rapport preliminare. Eur. J. Rheumatol. Inflammation 1978; 1: 73–76
   Google Scholar